Antibody Treatment of Ebola and Sudan Virus Infection via a Uniquely Exposed Epitope within the Glycoprotein Receptor-Binding Site
详细信息 查看全文
- 作者：Katie A. Howell1 ; Xiangguo Qiu2 ; 3 ; 4 ; Jennifer M. Brannan5 ; Christopher Bryan6 ; Edgar Davidson6 ; Frederick W. Holtsberg1 ; Anna Z. Wec10 ; Sergey Shulenin1 ; Julia E. Biggins1 ; Robin Douglas1 ; Sven G. Enterlein1 ; Hannah L. Turner7 ; Jesper Pallesen7 ; Charles D. Murin7 ; 8 ; Shihua He2 ; 3 ; 4 ; Andrea Kroeker2 ; 3 ; 4 ; Hong Vu1 ; Andrew S. Herbert5 ; Marnie L. Fusco8 ; Elisabeth K. Nyakatura11 ; Jonathan R. Lai11 ; Zhen-Yong Keck12 ; Steven K.H. Foung12 ; Erica Ollmann Saphire8 ; 9 ; Larry Zeitlin13 ; Andrew B. Ward7 ; Kartik Chandran10 ; Benjamin J. Doranz6 ; Gary P. Kobinger2 ; 3 ; 4 ; John M. Dye5 ; M. Javad Aman1 ; javad@integratedbiotherapeutics.com" class="auth_mail" title="E-mail the corresponding author
- 刊名：Cell Reports
- 出版年：2016
- 出版时间：17 May 2016
- 年：2016
- 卷：15
- 期：7
- 页码：1514-1526
- 全文大小：3429 K
文摘
- •
Monoclonal antibody FVM04 blocks interaction of ebolavirus with its host receptor
- •
FVM04 cross-neutralizes and protects against EBOV and SUDV in rodents
- •
A new ZMapp version that includes FVM04 protects guinea pigs from EBOV and SUDV
- •
Specific GP mutations expose epitopes for FVM04 and other cross-neutralizing mAbs